Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Drotrecogin Alfa (Activated) Administered as a Continuous 96-hr Infusion to Adult Patients With Septic Shock

NCT00604214 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00604214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00604214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Drotrecogin Alfa (Activated) Administered as a Continuous 96-hr Infusion to Adult Patients With Septic Shock
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2008
Completion date
February 29, 2012
Enrollment
1,696 (actual)
Sites
150

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis